

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2016/090022 A8

(43) International Publication Date
9 June 2016 (09.06.2016)

- (51) International Patent Classification:
C07K 14/005 (2006.01) *A61K 38/16* (2006.01)
- (21) International Application Number:
PCT/US2015/063476
- (22) International Filing Date:
2 December 2015 (02.12.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/087,052 3 December 2014 (03.12.2014) US
- (71) Applicant: **NEUROPHAGE PHARMACEUTICALS, INC.** [US/US]; 222 Third Street, Suite 3120, Cambridge, MA 02142 (US).
- (72) Inventors: **KRISHNAN, Rajaraman**; 281 Winter Street, Ashland, MA 01721 (US). **ASP, Eva**; 31 Bow Road, Newton, MA 02459 (US). **PROSCHITSKY, Ming**; 98 Wildwood Street, Winchester, MA 10890 (US). **FISHER, Richard**; 98 Wildwood Street, Winchester, MA 10890 (US). **CARR, Francis, J.**; Birchlea, The Holdings, Balmedie, Aberdeen AB23 8WU (GB). **HOLGATE, Robert, G.E.**; 22 Stamford Avenue, Royston, Hertfordshire SG8 7DD (GB). **JONES, Timothy, D.**; 27 Brick Row, Babraham, Cambridge CB22 3AJ (GB).
- (74) Agents: **MCDONELL, Leslie** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 901 New York Avenue, NW, Washington, DC 20001-4413 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

- (48) Date of publication of this corrected version:

14 July 2016

- (15) Information about Correction:
see Notice of 14 July 2016

(54) Title: POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE LACKING A GLYCOSYLATION SIGNAL

(57) Abstract: The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid deletion, insertion or substitution to remove a putative glycosylation signal. The invention further relates to such polypeptides that are also modified through additional amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability to bind and/or disaggregate amyloid. The invention further relates to the use of these g3p-modified polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.



WO 2016/090022 A8